' We Finally Made It ' : Amivantamab Comes of Age in NSCLC ' We Finally Made It ' : Amivantamab Comes of Age in NSCLC

Data from three trials with the amivantamab in advanced EGFR-mutant NSCLC have yielded"exciting" results with experts hailing the drug as standard of care in various settings.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news